Indegene
- Market cap
- ₹ 13,763 Cr.
- P/E
- 33.1x
- P/B
- 4.51x
- 52-week range
- 414 – 627
- ROE
- 14%
- ROCE
- 19%
- Dividend yield
- 0.4%
- Debt / equity
- 0.05
- Sector
- Healthcare Services
- Industry
- Healthcare Research, Analytics & Technology
- Listed on
- NSE, BSE
About
Indegene Limited is an India-based tech-native, life sciences commercialization company. The Company provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies. Its segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Brand Activation, and Others. The Enterprise Commercial Solutions business unit caters to the digital marketing operations of life sciences companies. The Enterprise Medical Solutions consolidates large-scale regulatory and medical operations for life sciences companies. The Brand Activation segment offers promotion of biopharmaceutical products and medical devices to HCPs for life sciences companies across channels. It provides customized marketing campaigns through a comprehensive portfolio of proprietary program offerings. Others mainly consist of consultancy and clinical business.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Research, Analytics & Technology: 11 companies →Indegene against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)33.1 against a typical 34.2: cheaper than most peers (1st = cheapest).5th of 11
- Sales growth+39.7% against a typical +16.4% from a year earlier.4th of 10
- Profit growth0% against a typical 0% from a year earlier.3rd of 5
- Share price, 3 months+14% against a typical −13%.2nd of 11
- Size₹ 13,762.8 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).2nd of 11
Latest announcements
Exchange filings and their impact on the company.
- Indegene incorporated a wholly owned Portugal subsidiary, a small EU expansion step with no near-term financial impact.
Indegene Limited incorporated a step-down wholly owned subsidiary, INDEGENE PORTUGAL, UNIPESSOAL LDA, in Portugal on 23 October 2026, 100% held via Indegene Ireland Limited. No share capital, investment amount or business plan was disclosed. It is an early EU footprint expansion step with no meaningful revenue or profit expected in the next 12 months.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 30 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 Apr 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 29 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 30 Oct 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 28 Apr 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025, and to recommend final dividend. |
| 30 Jan 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2024 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 636 | 673 | 673 | 676 | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 |
| Expenses | 515 | 524 | 534 | 548 | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 |
| Operating Profit | 121 | 149 | 139 | 129 | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 |
| OPM % | 19% | 22% | 21% | 19% | 18% | 18% | 20% | 20% | 17% | 17% | 16% | 16% |
| Other Income | 12 | 13 | 26 | 22 | 21 | 38 | 26 | 22 | 20 | 19 | −10 | 29 |
| Interest | 12 | 12 | 12 | 12 | 4 | 3 | 3 | 4 | 4 | 5 | 7 | 6 |
| Depreciation | 20 | 18 | 18 | 20 | 19 | 20 | 21 | 22 | 23 | 40 | 42 | 44 |
| Profit before tax | 101 | 132 | 134 | 120 | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 |
| Tax % | 25% | 25% | 29% | 27% | 26% | 25% | 21% | 23% | 23% | 24% | 24% | 24% |
| Net Profit | 75 | 99 | 95 | 88 | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 |
| EPS in Rs | 3.38 | 4.45 | 4.26 | 3.67 | 3.83 | 4.58 | 4.9 | 4.85 | 4.25 | 4.28 | 3.31 | 4.82 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 29%
- 3 Years
- 15%
- TTM
- 30%
- 10 Years
- —
- 5 Years
- 23%
- 3 Years
- 16%
- TTM
- −4%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 21%
- 3 Years
- 19%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Indegene | ₹ 598.00 | ₹ 13,763 Cr. | 33.1x | 4.5x | 14% | — |
| Delhivery | ₹ 370.00 | ₹ 27,724 Cr. | 226x | 3.8x | 1.6% | 1.5% |
| Urban Company | ₹ 132.65 | ₹ 20,457 Cr. | — | 8.9x | −11.9% | −15.1% |
| BLS International Services | ₹ 208.70 | ₹ 8,593 Cr. | 14.2x | 3.9x | 32.7% | 24.1% |
| Axiscades Technologies | ₹ 1,915.00 | ₹ 8,154 Cr. | 83.3x | 9.1x | 10.5% | 6.2% |
| TVS Supply Chain Solutions | ₹ 108.85 | ₹ 5,045 Cr. | 26.7x | 3x | 6% | 1.1% |
Management
- Manish Gupta
- Executive Chairman of the Board, Chief Executive Officer
- Suhas Prabhu
- Chief Financial Officer
- Sanjay Suresh Parikh
- Executive Vice President, Executive Director
- Anand Kiran Praf Nijegal
- Executive Vice President - Global Operations
- Srishti Ramesh Kaushik
- Compliance Officer, Company Secretary
- Viveksheel Ghai
- Executive Vice President - Enterprise Commercial Solutions of Indegene, Inc.
- Gaurav Kapoor
- Executive Vice President of Indegene, Inc.
- Sameer Lal
- Senior Vice President - Business Development of Indegene, Inc.
Prices are delayed and for information only. Nothing on this page is investment advice.